Jon C. Jones

2.7k total citations
25 papers, 1.7k citations indexed

About

Jon C. Jones is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jon C. Jones has authored 25 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jon C. Jones's work include Bone health and treatments (12 papers), Bone Metabolism and Diseases (11 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Jon C. Jones is often cited by papers focused on Bone health and treatments (12 papers), Bone Metabolism and Diseases (11 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Jon C. Jones collaborates with scholars based in United States, Switzerland and Cuba. Jon C. Jones's co-authors include Joanne L. Viney, William C. Dougall, Robert E. Miller, Ryan Erwert, Allison P. Jacob, Dan Branstetter, Eva González‐Suárez, Jan Pinkas, Allison Armstrong and Evan T. Keller and has published in prestigious journals such as Nature, Blood and The Journal of Immunology.

In The Last Decade

Jon C. Jones

25 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon C. Jones United States 16 1.1k 712 345 247 246 25 1.7k
J Treleaven United Kingdom 28 515 0.5× 397 0.6× 332 1.0× 113 0.5× 169 0.7× 71 2.0k
Francesco Pantano Italy 25 993 0.9× 861 1.2× 71 0.2× 208 0.8× 577 2.3× 109 2.1k
E. Thiel Germany 28 646 0.6× 698 1.0× 87 0.3× 269 1.1× 172 0.7× 121 2.5k
Giovanna Masci Italy 21 789 0.7× 471 0.7× 175 0.5× 135 0.5× 526 2.1× 73 1.6k
Denis Cournoyer Canada 23 434 0.4× 708 1.0× 284 0.8× 304 1.2× 55 0.2× 42 1.5k
Lydia Campos France 29 912 0.8× 1.7k 2.3× 113 0.3× 63 0.3× 220 0.9× 106 3.3k
Neeha Zaidi United States 20 994 0.9× 527 0.7× 70 0.2× 69 0.3× 278 1.1× 47 1.6k
Bo Chen China 23 758 0.7× 875 1.2× 98 0.3× 155 0.6× 440 1.8× 114 1.9k
Hyeoung‐Joon Kim South Korea 29 909 0.8× 1.0k 1.4× 110 0.3× 111 0.4× 165 0.7× 213 3.0k

Countries citing papers authored by Jon C. Jones

Since Specialization
Citations

This map shows the geographic impact of Jon C. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon C. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon C. Jones more than expected).

Fields of papers citing papers by Jon C. Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon C. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon C. Jones. The network helps show where Jon C. Jones may publish in the future.

Co-authorship network of co-authors of Jon C. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Jon C. Jones. A scholar is included among the top collaborators of Jon C. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon C. Jones. Jon C. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qin, Jim, Timothy G. Johnstone, Ronald J. Hause, et al.. (2020). Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. Journal of Immunotherapy. 43(4). 107–120. 60 indexed citations
2.
Works, Melissa, Neha Soni, Jon C. Jones, et al.. (2019). Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide. Molecular Cancer Therapeutics. 18(12). 2246–2257. 72 indexed citations
3.
Minn, Il, David Huss, Hye-Hyun Ahn, et al.. (2019). Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances. 5(7). eaaw5096–eaaw5096. 89 indexed citations
4.
O’Steen, Shyril, Melissa L. Comstock, Johnnie J. Orozco, et al.. (2019). The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood. 134(15). 1247–1256. 46 indexed citations
5.
Works, Melissa, Neha Soni, Jon C. Jones, et al.. (2017). Lenalidomide Enhances Anti-BCMA Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma. Blood. 130. 1794–1794. 2 indexed citations
6.
Welstead, G. Grant, Justin Fang, Frank A. Buquicchio, et al.. (2016). 572. Successful Generation of CAR+PD-1-Primary T Cells Using Cas9-Mediated Genome Editing. Molecular Therapy. 24. S229–S229. 2 indexed citations
7.
Miller, Brian W., Sofia H.L. Frost, Shani L. Frayo, et al.. (2015). Quantitative single‐particle digital autoradiography with α‐particle emitters for targeted radionuclide therapy using the iQID camera. Medical Physics. 42(7). 4094–4105. 56 indexed citations
8.
Green, Damian J., Jon C. Jones, Yukang Lin, et al.. (2015). A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. Blood. 126(23). 118–118. 1 indexed citations
9.
Miller, Robert E., Jon C. Jones, Mark Tometsko, Michelle Blake, & William C. Dougall. (2014). RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases. Journal of Thoracic Oncology. 9(3). 345–354. 33 indexed citations
10.
Green, Damian J., Nural Orgun, Jon C. Jones, et al.. (2013). A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies. Cancer Research. 74(4). 1179–1189. 40 indexed citations
11.
Blake, Michelle, Mark Tometsko, Robert E. Miller, Jon C. Jones, & William C. Dougall. (2013). RANK expression on breast cancer cells promotes skeletal metastasis. Clinical & Experimental Metastasis. 31(2). 233–245. 49 indexed citations
12.
Green, Damian J., Jon C. Jones, Mark D. Hylarides, et al.. (2013). Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model. Blood. 122(21). 882–882. 4 indexed citations
13.
Green, Damian J., Mazyar Shadman, Shani L. Frayo, et al.. (2013). Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model. Blood. 122(21). 4415–4415. 2 indexed citations
14.
Jacob, Allison P., Daniel Branstetter, Kathy Rohrbach, et al.. (2011). P3-01-14: RANK and RANK Ligand (RANKL) Expression in Invasive Breast Carcinoma and Human Breast Cancer Cell Lines.. Cancer Research. 71(24_Supplement). P3–1. 4 indexed citations
15.
Canon, Jude, R.J. Bryant, Martine P. Roudier, et al.. (2010). Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone. 46(6). 1613–1619. 30 indexed citations
16.
González‐Suárez, Eva, Allison P. Jacob, Jon C. Jones, et al.. (2010). RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 468(7320). 103–107. 431 indexed citations
17.
Holland, Pamela M., Robert E. Miller, Jon C. Jones, et al.. (2010). Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biology & Therapy. 9(7). 539–550. 33 indexed citations
18.
Branstetter, Dan, Allison P. Jacob, Eva González‐Suárez, et al.. (2009). RANKL inhibition decreases the incidence of mammary adenocarcinomas in wild type (WT) and MMTV-RANK transgenic mice.. Cancer Research. 69(2_Supplement). 4167–4167. 22 indexed citations
19.
Armstrong, Allison, Robert E. Miller, Jon C. Jones, et al.. (2007). RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. The Prostate. 68(1). 92–104. 142 indexed citations
20.
Jones, Jon C., et al.. (1998). A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdr1a, Spontaneously Develop Colitis. The Journal of Immunology. 161(10). 5733–5744. 437 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Treleaven Breakdown of academic impact, for papers by Francesco Pantano Breakdown of academic impact, for papers by E. Thiel Breakdown of academic impact, for papers by Giovanna Masci Breakdown of academic impact, for papers by Denis Cournoyer Breakdown of academic impact, for papers by Lydia Campos Breakdown of academic impact, for papers by Neeha Zaidi Breakdown of academic impact, for papers by Bo Chen Breakdown of academic impact, for papers by Hyeoung‐Joon Kim
Rankless by CCL
2026